Brown EJ, Frazier WA. Integrin-associated protein（CD47）and its ligands[J]. Trends Cell Biol, 2001, 11（3）：130-1355.
[2]
Jaiswal S, Jamieson CH, Pang WW, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis[J]. Cell, 2009, 138：271-285.
[3]
Poels LG, Peters D, van MY, et al. Monoclonal antibody against human ovarian tumor associated antigens[J]. J Natl Cancer Inst, 1986, 76：781-791.
[4]
Chao MP, Alizadeh AA, Tang C, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma[J]. Cell, 2010, 142：699-713.
[5]
Rendtlew Danielsen JM, Knudsen LM, Dahl IM, et al. Dysregulation of CD47 and the ligands thrombospondin 1 and 2 in multiple myeloma[J]. Br J Haematol, 2007, 138：756-760.
[6]
Willingham SB, Volkmer JP, Gentles AJ. The CD47-signal regulatory protein alpha（SIRPa）interaction is a therapeutic target for human solid tumors[J]. Proc Natl Acad Sci, 2012, 109（17）：6662-6667.
[7]
Serge M. Nanobodies：Natural single-domain antibodies[J]. Annual Review of Biochemistry, 2013, 82：17.1-17.23
[8]
Zhao XW, Taco WK, Timo KB. targeting of CD47-SIRP? Enough for treating hematopoietic malignancy[J]. BLOOD, 2012, 119：18.
[9]
Lauwereys M, Ghahroudi MA, Desmyter A, et al. Potent enzyme inhibitors derived from dromedary heavychain antibodies[J]. EMBO J, 1998, 17：3512-3520.
[10]
Chao MP, Weissman IL, Majeti R. The CD47-SIRPα pathway in can-cer immune evasion and potential therapeutic implications[J]. Curr Opin Immunol, 2012, 24（2）：225-232.
[11]
Sarfati M, Fortin G, Raymond M, et al. CD47 in the immune response：Role of thrombospondin and sirp-alpha reverse signaling[J]. Curr Drug Targets, 2008, 9（10）：842-850.
[12]
Chao MP, Alizadeh AA, Tang C, et al. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia[J]. Cancer Res, 2011, 71：1374-1384.
[13]
Chan KS, Espinosa I, Chao MP, et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells[J]. Proc Natl Acad Sci, 2009, 106：14016-14021.
[14]
Hamers-Casterman C, Atarhouch T, Muyldermans S, et al. Naturally occurring antibodies devoid of light chains[J]. Nature, 1993, 363（6428）：446-448.
[15]
De GE, Silence K, Decanniere K, et al. Molecular basis for the preferential cleft recognition by dromedary heavy- chain antibodies[J]. Proc Natl Acad Sci USA, 2006, 103（12）：4586-4591.
[16]
Daley LP, Gagliardo LF, Duffy MS, et al. Application of monoclonal antibodies in functional and comparative investigations of heavy-chain immunoglobulins in new world camelids[J]. Clin Diagn Lab Immunol, 2005, 12（3）：380-386.
[17]
Barclay AN, Van den Berg TK. The interaction between Signal Regulatory Protein Alpha（SIRPα）and CD47 structure, function, and therapeutic target[J]. Annu Rev Immunol, 2013, 32：25-50.
